| 翻訳と辞書 |
| pomalidomide ： ウィキペディア英語版 |
pomalidomide
Pomalidomide (INN, originally CC-4047 or 3-amino-thalidomide, trade name Pomalyst〔(【引用サイトリンク】url=http://www.pomalyst.com/ )〕 in the US and Imnovid in Europe) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma.〔(【引用サイトリンク】 url=http://www.myelomabeacon.com/news/2013/02/08/pomalyst-pomalidomide-fda-approval-multiple-myeloma/ )〕 It received a similar approval from the European Commission in August 2013.〔(【引用サイトリンク】 url=http://www.myelomabeacon.com/news/2013/08/09/pomalidomide-imnovid-pomalyst-europe-ema-approval-multiple-myeloma/ )〕
==Origin and development==
The parent compound of pomalidomide, thalidomide, was originally discovered to inhibit angiogenesis in 1994. Based upon this discovery, thalidomide was taken into clinical trials for cancer, leading to its ultimate FDA approval for multiple myeloma.〔http://vectorblog.org/2013/04/from-thalidomide-to-pomalyst-better-living-through-chemistry/〕 Structure-activity studies revealed that amino substituted thalidomide had improved antitumor activity, which was due to its ability to directly inhibit both the tumor cell and vascular compartments of myeloma cancers. This dual activity of pomalidomide makes it more efficacious than thalidomide ''in vitro'' and ''in vivo''.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「pomalidomide」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|